At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 90 enrolled
Drug / intervention
Dapagliflozin +2 moredrug
Likely dose
Dapagliflozin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in Type 2 Diabetes Mellitus (T2DM)
The University of Texas Health Science Center at San Antonio·interventional·Posted Dec 2, 2016·Updated Jul 20, 2023
In Brief
A Phase 4 clinical trial evaluating Dapagliflozin, Exenatide, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 90 participants across 1 site.
Detailed Summary
In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects. Researchers will examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartDec 2017
Primary CompletionJul 2022
Study CompletionMar 2023
TodayJul 2026
First PostedDec 2, 2016
Enrollment StartDec 15, 2017
Primary CompletionJul 14, 2022
Study CompletionMar 19, 2023
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 9.6 years ago
Interventions
Dapagliflozindrug
10mg
Exenatidedrug
Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)
Placebodrug
Placebo for Dapagliflozin